NCT04416334View on ClinicalTrials.gov

PREEMPTIVE THERAPY WITH COLCHICINE IN PATIENTS OLDER THAN 60 YEARS WITH HIGH RISK OF SEVERE PNEUMONIAE DUE TO CORONAVIRUS

PHASE3CompletedINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

August 19, 2020

Primary Completion Date

June 1, 2022

Study Completion Date

October 11, 2022

Conditions
SARS-CoV-2 Infection (COVID-19)
Interventions
DRUG

Colchicine plus symptomatic treatment (paracetamol)

Colchicine plus symptomatic treatment (paracetamol).

DRUG

Symptomatic treatment (paracetamol or best symptomatic treatment based on doctor recommendations)

Symptomatic treatment (paracetamol or best symptomatic treatment based on doctor recommendations).

Trial Locations (4)

Unknown

Atención primaria (Área 2), Laredo

Gerencia de atención primaria (Área 3), Reinosa

Atencion primaria (AREA 1), Santander

Gerencia de atención primaria (área 4), Torrelavega

All Listed Sponsors
collaborator

Gerencia de atención primaria área 1

UNKNOWN

collaborator

Gerencia de atención primaria área 2

UNKNOWN

collaborator

Gerencia Atencion Primaria Area 3

OTHER_GOV

collaborator

Gerencia de atención primaria área 4

UNKNOWN

lead

Instituto de Investigación Marqués de Valdecilla

OTHER

NCT04416334 - PREEMPTIVE THERAPY WITH COLCHICINE IN PATIENTS OLDER THAN 60 YEARS WITH HIGH RISK OF SEVERE PNEUMONIAE DUE TO CORONAVIRUS | Biotech Hunter | Biotech Hunter